null - FindTrial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225104

Enrollment

150

Registered

2020-03-03

Start date

2020-04-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

investigational material(s) Generic name etc : INN of investigational material : dupilumab Therapeutic category code : 449 Other antiallergic agents Dosage and Administration for Investigational mate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
efficacy	—

Secondary

Measure	Time frame
efficacy efficacy efficacy efficacy efficacy efficacy efficacy efficacy efficacy efficacy efficacy efficacy safety other	—

Countries

Asia except Japan, Europe, Japan, North America, South America

Outcome results